Welcome to our dedicated page for Proassurance Cp SEC filings (Ticker: PRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to U.S. Securities and Exchange Commission filings for ProAssurance Corporation (NYSE: PRA), a specialty property and casualty insurance holding company focused on medical professional liability, products liability for medical technology and life sciences, and workers’ compensation insurance. These regulatory documents offer detailed information on ProAssurance’s financial condition, segment performance, governance, and its pending merger with The Doctors Company.
ProAssurance’s periodic reports, such as its Form 10-K and Form 10-Q filings (referenced in the company’s earnings releases and 8-Ks), include consolidated financial statements, segment disclosures for Specialty Property and Casualty, Workers’ Compensation Insurance, Segregated Portfolio Cell Reinsurance, Lloyd’s Syndicate, and Corporate, as well as discussions of key ratios, Non-GAAP measures, and risk factors. Investors use these filings to analyze underwriting results, reserve development, investment income, and capital metrics like book value per share and Non-GAAP adjusted book value per share.
The company’s Form 8-K filings highlight specific material events. In 2025, ProAssurance filed multiple 8-Ks to furnish quarterly earnings releases under Item 2.02, report the June 24, 2025 stockholder vote approving the merger agreement with The Doctors Company under Item 5.07, and describe progress on regulatory milestones such as early termination of the Hart-Scott-Rodino waiting period under Item 8.01. Another 8-K filed in December 2025 under Item 5.02 outlines compensatory arrangements for named executive officers in connection with the merger and explains how these payments relate to Section 280G of the Internal Revenue Code.
On Stock Titan, ProAssurance filings are updated as they are released on EDGAR. AI-powered summaries help explain the contents of lengthy documents, highlight key changes from prior periods, and surface important items such as segment results, merger-related disclosures, and executive compensation arrangements. Users can review Forms 10-K and 10-Q for comprehensive financial information, 8-Ks for transaction and earnings announcements, and other filings that document ProAssurance’s regulatory history and its planned transition to a wholly owned subsidiary of The Doctors Company.
ProAssurance Corporation reported an equity compensation award to a senior executive. Executive Vice-President, Secretary & General Counsel Jeffrey Patton Lisenby received 23,720 Restricted Stock Units (RSUs) on
Each RSU represents a contingent right to one share of ProAssurance common stock under the 2014 Equity Incentive Compensation Plan. The new award will vest pro rata in one‑third increments in
ProAssurance Corporation’s President & CEO, Rand Edward Lewis Jr, reported an equity award in the form of restricted stock units. On January 7, 2026, he received 95,714 Restricted Stock Units (RSUs)$0 per unit, all held directly.
Each RSU gives a contingent right to one share of ProAssurance common stock under the company’s equity incentive plans. The newly reported RSUs tied to the 2014 Equity Incentive Compensation Plan are scheduled to vest in three equal installments in 2027, 2028, and 2029, as long as he remains employed with ProAssurance or its subsidiaries. Vesting can accelerate if his employment ends because of death, disability, Good Reason under his employment agreement, or by action of the Compensation Committee. When RSUs vest, they will be settled partly in shares and partly in cash to cover estimated taxes.
ProAssurance Corporation disclosed that its Chief Financial Officer, Dana S. Hendricks, received an award of 23,720 Restricted Stock Units (RSUs) on 01/07/2026. Each RSU represents a contingent right to receive one share of ProAssurance common stock under the ProAssurance Corporation 2014 Equity Incentive Compensation Plan.
According to the award terms, these RSUs will vest pro rata in one-third increments in each of the years 2027, 2028 and 2029, as long as the CFO remains continuously employed by ProAssurance or a subsidiary through each vesting date. Vesting will accelerate if employment ends due to death, disability or Good Reason, or by action of the Compensation Committee. The RSUs will be settled in shares of common stock and in cash, with the cash portion approximately equal to federal, state and local taxes.
ProAssurance Corporation reported an equity compensation grant to Kevin Merrick Shook, President of a subsidiary. On January 7, 2026, he received 23,720 Restricted Stock Units (RSUs) under the ProAssurance Corporation 2014 Equity Incentive Compensation Plan. These RSUs vest pro rata in one-third increments in 2027, 2028 and 2029, conditioned on his continued employment, with vesting accelerating upon death, disability, Good Reason as defined in his employment agreement, or action by the Compensation Committee. The RSUs will be settled in shares of ProAssurance common stock and cash to cover estimated taxes. Following this award, he directly holds this new RSU grant and additional RSUs from prior awards, including 17,668, 15,372 and 3,981 units.
ProAssurance Corporation granted equity compensation to a senior executive through restricted stock units. On January 7, 2026, Executive VP/Chief HR Officer Noreen Dishart received 18,477 Restricted Stock Units (RSUs) at a price of $0 per unit under the ProAssurance Corporation 2014 Equity Incentive Compensation Plan. Each RSU represents the right to receive one share of ProAssurance common stock plus a cash amount approximately equal to applicable taxes.
The newly granted RSUs are scheduled to vest in three equal installments in 2027, 2028, and 2029, subject to continued employment, with accelerated vesting upon death, disability, certain qualifying employment terminations, or action by the Compensation Committee. The filing also shows previously granted RSUs with post-transaction balances of 13,763, 3,101, and 11,974 units, all held directly.
ProAssurance Corporation reported an insider equity award for executive Francis Robert David, President, Healthcare Professional Liability. On January 7, 2026, he received 23,720 Restricted Stock Units (RSUs) at a price of $0 per unit under the ProAssurance Corporation 2014 Equity Incentive Compensation Plan.
Each RSU represents the right to receive one share of ProAssurance common stock. The new award will vest in three equal annual installments in 2027, 2028, and 2029, as long as he remains continuously employed with ProAssurance or a subsidiary. Vesting can accelerate if employment ends due to death, disability, Good Reason as defined in his employment agreement, or by action of the Board’s Compensation Committee. Settlement will be in ProAssurance shares plus a cash amount approximately equal to applicable taxes.
ProAssurance Corporation reports a compensation decision tied to its pending merger with The Doctors Company. To address potential “excess parachute payment” issues under Section 280G of the tax code, the board’s Compensation Committee, in consultation with TDC and pursuant to the merger agreement, approved paying the company’s named executive officers approximately 80% of the annual cash incentive awards that are presently expected for 2025.
On December 5, 2025, the authorized payments were $998,400 for CEO Edward L. Rand, Jr., $369,873 for CFO Dana S. Hendricks, $381,998 for EVP/General Counsel Jeffrey P. Lisenby, $348,098 for Eastern Alliance Insurance Group President Kevin M. Shook, and $450,000 for Medical Professional Liability President Robert D. Francis. The committee based its decision on its assessment of the likelihood of achieving 2025 performance targets outlined in the 2025 proxy statement.
AllianceBernstein L.P. filed a Schedule 13G disclosing beneficial ownership of 2,711,805 ProAssurance (PRA) common shares, representing 5.3% of the class as of 09/30/2025. The firm reports sole voting power over 1,691,153 shares and sole dispositive power over 2,711,805 shares, with no shared voting or dispositive power.
The filing states the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
ProAssurance (PRA) reported third‑quarter results and updated its pending merger with The Doctors Company. Total revenues were $279,554 (in thousands)net income was $1,446 (in thousands), for EPS of $0.03. Net premiums earned were $233,404 (in thousands) and net investment income was $40,442 (in thousands). Expenses totaled $275,185 (in thousands), driven by losses and loss adjustment expenses of $186,199 (in thousands) and operating expense of $46,817 (in thousands).
On the balance sheet, shareholders’ equity rose to $1,304,252 (in thousands), as accumulated other comprehensive loss improved to $(90,841) from $(172,391) at year‑end, while the reserve for losses and LAE decreased to $3,118,937 (in thousands). Year‑to‑date operating cash flow was $(12,476) (in thousands).
The company continues to pursue its all‑cash merger at $25.00 per share. Stockholders approved the deal; HSR early termination was granted, and regulatory approvals have been received in Alabama, the District of Columbia, Illinois, Missouri and Vermont, with reviews pending in California, Pennsylvania and Texas. Transaction costs were $3.0 million in Q3 and $14.6 million year‑to‑date. The company anticipates closing by June 30, 2026, subject to remaining conditions.
ProAssurance Corporation filed an 8‑K stating it furnished a news release with results for the quarter ended September 30, 2025. The release is included as Exhibit 99.1.
The company also updated its online disclosure of its entire investment portfolio through September 30, 2025, available under Quarterly Results in the Financial Information section of its Investor Relations website. The furnished information, including Exhibit 99.1, is not deemed “filed” under the Exchange Act.